MA42442B1 - Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate - Google Patents
Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamateInfo
- Publication number
- MA42442B1 MA42442B1 MA42442A MA42442A MA42442B1 MA 42442 B1 MA42442 B1 MA 42442B1 MA 42442 A MA42442 A MA 42442A MA 42442 A MA42442 A MA 42442A MA 42442 B1 MA42442 B1 MA 42442B1
- Authority
- MA
- Morocco
- Prior art keywords
- modulators
- glutamate receptor
- metabotropic glutamate
- compounds
- ethynyl derivatives
- Prior art date
Links
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Liquid Crystal (AREA)
Abstract
La présente invention concerne des composés de formule i dans laquelle r1 est un alkyle inférieur ; r2 est un phényle ou pyridinyle, l'atome n dans le groupe pyridinyle pouvant être à des positions différentes ; n est 0, 1 ou 2 ; v/u sont indépendamment l'un de l'autre o ou ch2, v et u ne pouvant pas être simultanément o ; et l est un groupe hétéroaryle à cinq ou six chaînons, ou un sel pharmaceutiquement acceptable ou un sel d'addition d'acide, un mélange racémique de ceux-ci, ou un énantiomère et/ou isomère optique et/ou stéréoisomère correspondant. Les composés peuvent être utilisés pour traiter la maladie de parkinson, l'anxiété, les vomissements, les troubles obsessionnels compulsifs, l'autisme, le cancer, la dépression et le diabète de type 2 ainsi que pour la neuroprotection.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15176854 | 2015-07-15 | ||
| PCT/EP2016/066393 WO2017009275A1 (fr) | 2015-07-15 | 2016-07-11 | Dérivés d'éthynyle a titre de modulateurs du récepteur métabotropique du glutamate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA42442A MA42442A (fr) | 2018-05-23 |
| MA42442B1 true MA42442B1 (fr) | 2019-07-31 |
Family
ID=53758003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42442A MA42442B1 (fr) | 2015-07-15 | 2016-07-11 | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10189848B2 (fr) |
| EP (1) | EP3322701B1 (fr) |
| JP (1) | JP6761821B2 (fr) |
| KR (1) | KR20180026438A (fr) |
| CN (1) | CN107580598B (fr) |
| AR (1) | AR105341A1 (fr) |
| AU (1) | AU2016292863B2 (fr) |
| CA (1) | CA2984711C (fr) |
| CL (1) | CL2018000036A1 (fr) |
| CO (1) | CO2017011174A2 (fr) |
| CR (1) | CR20180022A (fr) |
| DK (1) | DK3322701T3 (fr) |
| ES (1) | ES2733468T3 (fr) |
| HR (1) | HRP20191139T1 (fr) |
| HU (1) | HUE045145T2 (fr) |
| IL (1) | IL255096B (fr) |
| LT (1) | LT3322701T (fr) |
| MA (1) | MA42442B1 (fr) |
| MX (1) | MX374409B (fr) |
| PE (1) | PE20180356A1 (fr) |
| PH (1) | PH12018500106A1 (fr) |
| PL (1) | PL3322701T3 (fr) |
| PT (1) | PT3322701T (fr) |
| RS (1) | RS58929B1 (fr) |
| RU (1) | RU2721776C9 (fr) |
| SI (1) | SI3322701T1 (fr) |
| TR (1) | TR201909160T4 (fr) |
| TW (1) | TWI612962B (fr) |
| UA (1) | UA120463C2 (fr) |
| WO (1) | WO2017009275A1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
| LT2986610T (lt) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicikliniai heterociklai, kaip fgfr inhibitoriai |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| ES2733468T3 (es) | 2015-07-15 | 2019-11-29 | Hoffmann La Roche | Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato |
| SI3484889T1 (sl) | 2016-07-18 | 2020-11-30 | F. Hoffmann-La Roche Ag | Derivati etinila |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| ES3061844T3 (en) | 2018-05-04 | 2026-04-07 | Incyte Corp | Salts of an fgfr inhibitor |
| MX2020011718A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas. |
| CA3102326A1 (fr) | 2018-07-26 | 2020-01-30 | Domain Therapeutics | Derives de quinazolinone substitues et leur utilisation en tant que modulateurs allosteriques positifs de mglur4 |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI891666B (zh) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | 作為ｆｇｆｒ抑制劑之雙環雜環 |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| CA3163875A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Heterocycles tricycliques en tant qu'inhibiteurs de fgfr |
| WO2021113462A1 (fr) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Dérivés d'un inhibiteur de fgfr |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TW202304459A (zh) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法 |
| EP4352060A1 (fr) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Hétérocycles tricycliques utiles en tant qu'inhibiteurs de fgfr |
| JP2024522189A (ja) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式ヘテロ環 |
| KR20250156792A (ko) * | 2023-03-10 | 2025-11-03 | 브라이트씨드, 인크. | 스트레스 조절을 위한 조성물 및 방법 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875433B2 (en) | 2002-08-23 | 2005-04-05 | The United States Of America As Represented By The Secretary Of The Army | Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein |
| KR101333861B1 (ko) * | 2005-05-24 | 2013-11-28 | 메르크 세로노 에스. 에이. | Ｃｒｔｈ２ 조정자로서 삼환계 스피로 유도체 |
| JP2010502617A (ja) | 2006-08-31 | 2010-01-28 | シェーリング コーポレイション | 抗菌物質として有用なヒダントイン誘導体 |
| NZ581817A (en) | 2007-06-03 | 2012-05-25 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
| EP2262832A4 (fr) | 2008-02-01 | 2011-03-09 | Ca Minister Health & Welfare | Anticorps monoclonaux contre les virus d'ebola et de marburg |
| ES2400515T3 (es) | 2009-01-19 | 2013-04-10 | Fondazione Irccs "Ca' Granda - Ospedale Maggiore Policlinico" | Análogos de melanocortina con actividad antimicrobiana |
| WO2011071574A2 (fr) | 2009-09-02 | 2011-06-16 | United States Deparment Of The Army, As Represented By The Secretary Of The Army | Anticorps monoclonaux dirigés contre la glycoprotéine du virus ebola souche soudan boniface |
| CA2773038A1 (fr) | 2009-09-04 | 2011-03-10 | P. Jeffrey Conn | Potentialisateurs allosteriques mglur4, composition et methodes de traitement de dysfonctionnements neurologiques |
| US8389536B2 (en) | 2009-10-27 | 2013-03-05 | Hoffmann-La Roche Inc. | Positive allosteric modulators (PAM) |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8586581B2 (en) | 2009-12-17 | 2013-11-19 | Hoffmann-La Roche Inc | Ethynyl compounds useful for treatment of CNS disorders |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US8772300B2 (en) | 2011-04-19 | 2014-07-08 | Hoffmann-La Roche Inc. | Phenyl or pyridinyl-ethynyl derivatives |
| MY165141A (en) | 2011-04-26 | 2018-02-28 | Hoffmann La Roche | Pyrazolidin-3-one derivatives |
| KR101554803B1 (ko) | 2011-04-26 | 2015-09-21 | 에프. 호프만-라 로슈 아게 | Mglur5의 양성 알로스테릭 조절체로서 에틴일 유도체 |
| WO2012162635A1 (fr) | 2011-05-26 | 2012-11-29 | Sunovion Pharmaceuticals Inc. | Modulateurs des récepteurs 5 métabotropiques du glutamate et leurs procédés d'utilisation |
| US20130123254A1 (en) | 2011-09-30 | 2013-05-16 | Barbara Biemans | Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification |
| UA110995C2 (uk) | 2011-10-07 | 2016-03-10 | Ф. Хоффманн-Ля Рош Аг | Етинільні похідні як модулятори метаботропного глутаматного рецептора |
| UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
| WO2014012851A1 (fr) | 2012-07-17 | 2014-01-23 | F. Hoffmann-La Roche Ag | Dérivés d'aryléthynyle |
| AU2013333984B2 (en) | 2012-10-18 | 2017-03-09 | F. Hoffmann-La Roche Ag | Ethynyl derivatives as modulators of mGluR5 receptor activity |
| EA026941B1 (ru) | 2012-10-18 | 2017-06-30 | Ф. Хоффманн-Ля Рош Аг | ПРОИЗВОДНЫЕ ЭТИНИЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ АКТИВНОСТИ РЕЦЕПТОРА mGluR5 |
| CN105121424B (zh) | 2013-02-18 | 2019-01-22 | 华领医药技术（上海）有限公司 | mGluR调节剂 |
| UY35400A (es) | 2013-03-15 | 2014-10-31 | Novartis Ag | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| CN105579447B (zh) | 2013-09-25 | 2018-11-13 | 豪夫迈·罗氏有限公司 | 乙炔基衍生物 |
| TWI649310B (zh) * | 2014-01-10 | 2019-02-01 | 赫孚孟拉羅股份公司 | 乙炔基衍生物 |
| EP3107567A4 (fr) | 2014-02-19 | 2017-10-25 | Cangene Corporation | Procédés de modulation d'une réponse immunitaire |
| CN104860941B (zh) | 2014-02-25 | 2017-03-22 | 上海海雁医药科技有限公司 | 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 |
| UA117855C2 (uk) | 2014-02-25 | 2018-10-10 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу |
| SG10201902924RA (en) | 2014-10-03 | 2019-05-30 | Massachusetts Inst Technology | Antibodies that bind ebola glycoprotein and uses thereof |
| WO2016146600A1 (fr) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Dérivés 3-(4-éthynylphényl)hexahydropyrimidine-2,4-dione en tant que modulateurs de mglur4 |
| ES2733468T3 (es) | 2015-07-15 | 2019-11-29 | Hoffmann La Roche | Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato |
| SI3484889T1 (sl) | 2016-07-18 | 2020-11-30 | F. Hoffmann-La Roche Ag | Derivati etinila |
-
2016
- 2016-07-11 ES ES16739442T patent/ES2733468T3/es active Active
- 2016-07-11 RS RS20190819A patent/RS58929B1/sr unknown
- 2016-07-11 RU RU2018103944A patent/RU2721776C9/ru active
- 2016-07-11 MX MX2018000592A patent/MX374409B/es active IP Right Grant
- 2016-07-11 LT LTEP16739442.8T patent/LT3322701T/lt unknown
- 2016-07-11 EP EP16739442.8A patent/EP3322701B1/fr active Active
- 2016-07-11 UA UAA201801133A patent/UA120463C2/uk unknown
- 2016-07-11 SI SI201630292T patent/SI3322701T1/sl unknown
- 2016-07-11 CR CR20180022A patent/CR20180022A/es unknown
- 2016-07-11 PT PT16739442T patent/PT3322701T/pt unknown
- 2016-07-11 CA CA2984711A patent/CA2984711C/fr active Active
- 2016-07-11 DK DK16739442.8T patent/DK3322701T3/da active
- 2016-07-11 AU AU2016292863A patent/AU2016292863B2/en not_active Ceased
- 2016-07-11 JP JP2017564709A patent/JP6761821B2/ja active Active
- 2016-07-11 KR KR1020187000004A patent/KR20180026438A/ko active Pending
- 2016-07-11 MA MA42442A patent/MA42442B1/fr unknown
- 2016-07-11 TR TR2019/09160T patent/TR201909160T4/tr unknown
- 2016-07-11 WO PCT/EP2016/066393 patent/WO2017009275A1/fr not_active Ceased
- 2016-07-11 HU HUE16739442A patent/HUE045145T2/hu unknown
- 2016-07-11 CN CN201680026777.2A patent/CN107580598B/zh active Active
- 2016-07-11 HR HRP20191139TT patent/HRP20191139T1/hr unknown
- 2016-07-11 PL PL16739442T patent/PL3322701T3/pl unknown
- 2016-07-11 PE PE2017002337A patent/PE20180356A1/es unknown
- 2016-07-13 AR ARP160102117A patent/AR105341A1/es unknown
- 2016-07-14 TW TW105122266A patent/TWI612962B/zh active
-
2017
- 2017-10-17 IL IL255096A patent/IL255096B/en active IP Right Grant
- 2017-10-30 CO CONC2017/0011174A patent/CO2017011174A2/es unknown
-
2018
- 2018-01-05 CL CL2018000036A patent/CL2018000036A1/es unknown
- 2018-01-12 PH PH12018500106A patent/PH12018500106A1/en unknown
- 2018-01-12 US US15/869,268 patent/US10189848B2/en active Active
- 2018-12-14 US US16/220,512 patent/US11034699B2/en active Active
-
2021
- 2021-05-09 US US17/315,349 patent/US12006323B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42442A (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| MA35133B1 (fr) | Dérivés d'éthynyle comme modulateurs allostériques positifs de mglur5 | |
| MA38272A1 (fr) | Peptides en tant qu'agonistes de l'oxytocine | |
| MA31865B1 (fr) | Dérivés isoxazolo-pyridine | |
| MA38012B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5 | |
| MA53668B1 (fr) | Traitement de la drépanocytose avec un composé activant la pyruvate kinase r | |
| MA35062B1 (fr) | Dérivés d'amines hétérocycliques | |
| MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
| MA38325A2 (fr) | Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes | |
| PE20040164A1 (es) | Mimeticos de glucocorticoides, procedimientos para su preparacion y composiciones farmaceuticas | |
| WO2019007696A1 (fr) | Nouveaux composés et compositions pharmaceutiques de ceux-ci destinés au traitement de la fibrose | |
| MA35113B1 (fr) | 5-(phényl/pyridinyl-éthinyl)-2-pyridine/2 pyrimidine-carboxamides comme modulateur de mglur5 | |
| MA35192B1 (fr) | Derives de pyrazole | |
| MA38885A1 (fr) | Dérivés d'éthynyle modulateurs allosteriques positifs (pam) du recepteur metabotropique du glutamate 4 (mglu4) | |
| MA54447B1 (fr) | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés similaires en tant que modulateurs de la secretase gamma pour le traitement de la maladie d'alzheimer | |
| PH12016501100B1 (en) | Ethynyl-imidazolin-2,4-dione derivatives as mglur4 modulators | |
| MX2016000895A (es) | Derivados de 1,7-naftiridina. | |
| MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
| MA29809B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
| MA38659B1 (fr) | Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate | |
| MA38011B1 (fr) | Dérivés d'éthynyle comme modulateurs de l'activité du récepteur mglur5 | |
| MX2020008523A (es) | Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5). | |
| MA45665B1 (fr) | Dérivés d'éthynyle | |
| MA29806B1 (fr) | Derives de 2-aminothiazoles et 2- aminooxazoles,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
| TH1701007595A (th) | อนุพันธ์เอไทนิลในฐานะโมดูเลเตอร์ของเมทาโบโทรปิกกลูตาเมตรีเซปเตอร์ |